Eli Lilly (LLY) Receivables - Net (2009 - 2026)

Eli Lilly (LLY) has reported Receivables - Net for 18 consecutive years, with $18.4 billion the latest figure, recorded in Q1 2026.

• Receivables - Net for Q1 2026 came in at $18.4 billion, up 53.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.4 billion (up 53.11% YoY), and the FY2025 annual result was $17.8 billion, up 61.37% from the prior year.
• Receivables - Net was $18.4 billion for Q1 2026 at Eli Lilly, up from $17.8 billion in the prior quarter.
• Over five years, Receivables - Net peaked at $18.4 billion in Q1 2026 and troughed at $6.3 billion in Q1 2022.
• Average Receivables - Net over 5 years is $10.4 billion, with a median of $9.1 billion recorded in 2023.
• Year-over-year, Receivables - Net gained 3.34% in 2022 and soared 61.37% in 2025.
• Over 5 years, Receivables - Net stood at $6.9 billion in 2022, then surged by 31.82% to $9.1 billion in 2023, then increased by 21.07% to $11.0 billion in 2024, then jumped by 61.37% to $17.8 billion in 2025, then increased by 3.77% to $18.4 billion in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $18.4 billion in Q1 2026, $17.8 billion in Q4 2025, and $16.1 billion in Q3 2025.